JAK2基因突变与慢性髓系白血病易感性的meta分析

doi:10.3969/j.issn.1004-616x.2019.03.011

摘要/Abstract

摘要： 目的：探讨JAK2基因突变与慢性髓系白血病（CML）的关系。方法：检索中国知网（CNKI）、维普（VIP）、万方、PubMed、Web of Science、CBM数据库中关于JAK2突变与CML关系的文章。检索时间截至2018年9月，由两位研究者独立按照纳入与排除标准筛选文献，提取资料后，用纽卡斯尔-渥太华量表（NOS）评分进行质量评价。采用Stata 11.0、RevMan 5.3软件进行meta分析。结果：共纳入15篇文章，包含总病例数1 684例，JAK2基因突变104例（突变位点分别位于第12和第14号外显子编码序列的第1 849位碱基G被T取代）。Meta分析结果显示CML患者的JAK2基因突变率为0.08[95% CI （0.05，0.11）]，亚组分析显示费城染色体（Ph）和JAK2是否突变、不同地区的突变分布、外显子的突变位点是异质性的主要来源。结论：慢性髓系白血病细胞JAK2基因外显子12和14突变、突变体JAKV617F的存在可能促使CML的发生。

关键词: JAK2, 基因突变, 慢性髓系白血病, meta分析

Abstract: OBJECTIVE:To investigate the association between JAK2 gene mutation and development of chronic myeloid leukemia (CML). METHODS: A systematic literature searches of CNKI, VIP, Wanfang, PubMed,Web of Science and CBM databases were conducted in September 2018. The identified publications were screened for inclusion and exclusion criteria by two researchers independently. Data were extracted from selected papers and evaluated for quality using a modified NOS score. Meta-analyses were performed by using the Stata 11.0 and RevMan 5.3 software. RESULTS:A total of 15 articles were selected which included 1 684 cases and 104 mutations (JAK2V617F mutation is characterized by a G to T transversion at nucleotide 1 849 in exon 12 or exon 14 of the gene). Meta-analyses show that the mutation rate of JAK2 in CML patients was 0.08[95%CI (0.05,0.11)]. Subgroup analyses show that the main reason for heterogeneity of whether Ph and JAK2 mutations involved different regions and exon mutation site. CONCLUSION:The JAK2 exon 12 and 14 mutations and mutant JAKV617F were associated with the development of CML.

Key words: JAK2, gene mutation, chronic myeloid leukemia, meta-analysis

中图分类号:

R557+.3

杨谨如, 秦露露, 朱勇飞. JAK2基因突变与慢性髓系白血病易感性的meta分析[J]. 癌变·畸变·突变, 2019, 31(3): 231-237.

YANG Jinru, QIN Lulu, ZHU Yongfei. Meta analysis on association between JAK2 gene mutation and susceptibility to chronic myeloid leukemia[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 231-237.

参考文献

[1] REDDY E P, AGGARWAL A K. The ins and outs of bcr-abl inhibition[J]. Genes Cancer, 2012, 3(5/6):447-454.
[2] 王斯婷,艾欣. "陆勇案"的背后——伊马替尼在中国的专利状况分析[J]. 中国发明与专利,2016(5):110-115.
[3] CELLA D, NOWINSKI C J, FRANKFURT O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia[J]. Oncology,2014,87(3):133-147.
[4] EGAN D, RADICH J. Monitoring disease burden in chronic myeloid leukemia:Past, present, and future[J]. Am J Hematol,2016,91(7):742-746.
[5] 宋君红,张苏江,李建勇. JAK2基因突变与慢性骨髓增殖性疾病[J]. 中华血液学杂志,2006(10):713-715.
[6] XING S, WANTING T H, ZHAO W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice[J]. Blood,2008,111(10):5109-5117.
[7] 赵一鸣. JAK2V617F在骨髓增殖性肿瘤中的研究及临床意义[D]. 合肥:安徽医科大学,2011.
[8] 曾宪涛,刘慧,陈曦,等. Meta分析系列之四:观察性研究的质量评价工具[J]. 中国循证心血管医学杂志,2012, (4):297-299.
[9] MOHER D, LIBERATI A, TETZLAFF J, et al. Preferred reporting items for systematic reviews and metaanalyses:the PRISMA statement[J]. J Clin Epidemiol, 2009,62(10):1006-1012.
[10] LEWANDOWSKI K, GNIOT M, WOJTASZEWSKA M, et al. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors[J]. Int J Lab Hematol,2018,40(3):366-371.
[11] PAHORE Z A, SHAMSI T S, TAJ M, et al. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression[J]. J Coll Phys Surg Pak,2011, 21(8):472-475.
[12] BENMOUSSA A, DEHBI H, FEHRI S, et al. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders:Contribution, diagnosis and therapeutic prospects[J]. Pathol Biol, 2011, 59(4):e89-e92.
[13] JELINEK J, OKI Y, GHARIBYAN V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML,Philadelphia chromosome-negative CML, and megakaryocytic leukemia[J]. Blood, 2005, 106(10):3370-3373.
[14] LEVINE R L,LORIAUX M,HUNTLY B J,et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia,but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia[J]. Blood,2005,106(10):3377-3379.
[15] TABASSUM N, SABOOR M, GHANI R, et al. Frequency of JAK2 V617F mutation in patients with Philadelphia positive chronic myeloid leukemia in Pakistan[J]. Pak J Med Sci,2014,30(1):185-188.
[16] VALIKHANI A, POOPAK B, FERDOWSI S, et al. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia[J]. Asia Pac J Clin Oncol,2017,13(2):e41-e47.
[17] 梅丽娜,王季石,卢英豪,等. 等位基因特异性-聚合酶链反应(ANS-PCR)检测慢性粒细胞白血病中(CML)中JAK2V617F点突变;[C]//贵州省医学会内科学分会2007年学术年会. 中国贵州贵阳,2007.
[18] TURAKHIA S K,MURUGESAN G,COTTA C V,et al. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations[J]. J Clin Pathol, 2016, 69(8):713-719.
[19] 张心菊,顾小叶,刘双春,等. 采用荧光定量PCR检测JAK2基因V617F突变[J]. 中华检验医学杂志,2009,32(5):583-586.
[20] BODDU P,CHIHARA D,MASAROVA L,et al. The cooccurrence of driver mutations in chronic myeloproliferative neoplasms[J]. Ann Hematol,2018,97(11):2071-2080.
[21] CHEN Y,FANG F,HU Y,et al. The polymorphisms in LNK gene correlated to the clinical type of myeloproliferative neoplasms[J]. PLoS One, 2016, 11(4):e0154183.
[22] SHAHIN A, ZEINAB G. Assessment of the chronic myeloproliferative disorders in patients with CML JAK2V617F mutation frequency of tabriz in iran by ARMS-PCR technique[J]. J Pharm Pharm Sci, 2015, 4(11):392-403.
[23] MANJULA G, PRAJITHA E M, SAILASA K, et al. JAK2 V617F mutation:a marker for cml progression?[J]. J Cell Tissue Res,2013,13(1):3439-3443.
[24] MHAA Al-KAABI,YUSRA G Y A,SHAHLA F S,et al. Incidence of JAK2 V617F mutation in IRAQI patients with Philadelphia positive CML[J]. Mint J Pharm Med Sci,2013:10-12.
[25] 金晓明. 晚期慢性粒细胞白血病ras癌基因突变罕见[J]. 国外医学遗传学分册,1990(5):271-272.
[26] XIAO X,JIANG K,XU Y,et al. (-)-Epigallocatechin-3-gallate induces cell apoptosis in chronic myeloid leukemia by regulating Bcr/Abl-mediated p38-MAPK/JNK and JAK2/STAT3/AKT signaling pathways[J]. Clin Exp Pharmacol Physiol,2019,46(2):126-136.
[27] 张菁. RAS突变很少发生于Ph染色体和bcr重排阴性的慢粒白血病,但常见于慢性粒单细胞白血病[J]. 国外医学输血及血液学分册,1991(3):174.
[28] 杨小飞. RAS基因突变和PHLPP1在髓系白血病中的作用[D]. 苏州:苏州大学,2013.
[29] GAMAL T E, MOHAMED G, OMINA S, et al. Prevalence of the frequency of JAK2(V617F) mutation in different myeloproliferative disorders in Egyptian patients[J]. Int J Clin Exp Pathol,2015,8(9):11555-11559.